» Articles » PMID: 30951682

MiR-34s Negatively Regulate Homologous Recombination Through Targeting RAD51

Overview
Publisher Elsevier
Specialties Biochemistry
Biophysics
Date 2019 Apr 6
PMID 30951682
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Double-strand breaks (DSBs), the most serious lesions of DNA, often induce chromosomal aberrations and are intimately associated with oncogenesis. A normal DNA damage response (DDR) network contains two major repair pathways: homologous recombination (HR) and non-homologous end-joining (NHEJ). Studies of DSB repair-associated molecules have focused mainly on DNA repair proteins. However, non-coding RNAs also play important roles in the process of DSB repair. Over the past two decades, microRNAs (miRNAs) have been extensively investigated. Our previous work showed that miR-34c-5p overexpression results in suppression of RAD51 and upregulation of γH2AX. In accordance with this, we confirmed that miR-34s family overexpression increased endogenous DSB levels to different extents, an effect that was further confirmed to be associated with the decreased efficiency of HR repair. In addition, miR-34s overexpression also induced G1 arrest, inhibited proliferation and promoted apoptosis. As a central molecule in the process of HR pathway, RAD51 expression was strongly repressed in cells transfected with the miR-34a/b/c-5p mimic. Finally, we demonstrated that miR-34a/b/c-5p directly targets the RAD51 mRNA 3'-UTR or indirectly inhibits RAD51 expression via the p53 signaling pathway. Taken together, our results indicate that miR-34s overexpression depresses the efficiency of HR repair and induces DSBs by downregulating RAD51 expression. Our findings highlight a novel mechanism of HR pathway regulation via the miR-34s/p53/RAD51 axis.

Citing Articles

MiR-34b promotes oxidative stress and induces cellular senescence through TWIST1 in human cervical cancer.

Sindhu K, Nalini V, Suraishkumar G, Karunagaran D Transl Oncol. 2024; 48:102063.

PMID: 39094513 PMC: 11342277. DOI: 10.1016/j.tranon.2024.102063.


MiRNA-Based Therapies for Lung Cancer: Opportunities and Challenges?.

Yang H, Liu Y, Chen L, Zhao J, Guo M, Zhao X Biomolecules. 2023; 13(6).

PMID: 37371458 PMC: 10295928. DOI: 10.3390/biom13060877.


Identification of new RAD51D-regulating microRNAs that also emerge as potent inhibitors of the Fanconi anemia/homologous recombination pathways.

Hater N, Iwaniuk K, Leifeld C, Gruten P, Wiek C, Raba K Hum Mol Genet. 2022; 31(24):4241-4254.

PMID: 35904444 PMC: 9759333. DOI: 10.1093/hmg/ddac177.


The Role of MicroRNA in DNA Damage Response.

Li Y, Tong Y, Liu J, Lou J Front Genet. 2022; 13:850038.

PMID: 35591858 PMC: 9110863. DOI: 10.3389/fgene.2022.850038.


Molecular Mechanisms of Specific Cellular DNA Damage Response and Repair Induced by the Mixed Radiation Field During Boron Neutron Capture Therapy.

Maliszewska-Olejniczak K, Kaniowski D, Araszkiewicz M, Tyminska K, Korgul A Front Oncol. 2021; 11:676575.

PMID: 34094980 PMC: 8170402. DOI: 10.3389/fonc.2021.676575.